36. INITIAL STUDY TO DISTINGUISH LUNG CANCER AND BENIGN LUNG DISEASE USING SHOX2 GENE METHYL MARKER FROM LUNG BIOPSY AND LIQUID BIOPSY SAMPLE
Main Article Content
Abstract
This study explores the potential of SHOX2 DNA methylation as a biomarker to distinguish lung cancer from benign lung diseases. We conducted analyzes on both lung tissue samples and plasma samples from lung cancer patients and the control group. Using Realtime PCR technology with extendable lock probes and TaqMan probes, we aimed to increase the sensitivity and specificity of the method, which is important in handling samples with low tumor DNA concentrations. Results showed significant detection of SHOX2 methylation in lung cancer patients compared with controls, both in tissue and plasma samples, demonstrating the potential of this marker in early and non-invasive diagnosis of cancer. lung cancer. Statistical analysis confirmed significant differences between the two groups, reinforcing the role of SHOX2 as an effective biomarker. Although the results are promising, further research is needed to confirm the broad applicability of the method. Improving the chances of diagnosing and treating lung cancer, the study highlights the importance of developing new biomarkers and precise analysis technology.
Article Details
Keywords
DNA methylation; SHOX2; Lung cancer; Liquid biopsy; Realtime PCR.
References
Cancer Statistics 2020: GLOBOCAN Estimates
of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin,
71(3), 2021, 209–249.
[2] Wang S., Dong L., Wang X. et al., Classification
of Pathological Types of Lung Cancer from
CT Images by Deep Residual Neural Networks
with Transfer Learning Strategy. Open Med, 15,
2020, 190–197.
[3] Kalinke L., Thakrar R., Janes S.M., The promises
and challenges of early non‐small cell lung
cancer detection: Patient perceptions, low‐dose
CT screening, bronchoscopy and biomarkers.
Mol Oncol, 15(10), 2021, 2544–2564.
[4] Reduced Lung-Cancer Mortality with Low-Dose
Computed Tomographic Screening. N Engl J
Med, 365(5), 2011, 395–409.
[5] Kalari S., Jung M., Kernstine K.H. et al., The
DNA methylation landscape of small cell lung
cancer suggests a differentiation defect of neuroendocrine
cells. Oncogene, 32(30), 2013, 3559–3568.
[6] Rauch T., Wang Z., Zhang X. et al., Homeobox
gene methylation in lung cancer studied by genome-
wide analysis with a microarray-based
methylated CpG island recovery assay. Proc Natl
Acad Sci U S A, 104(13), 2007, 5527–5532.
[7] Rauch T.A., Zhong X., Wu X. et al., High-resolution
mapping of DNA hypermethylation and
hypomethylation in lung cancer. Proc Natl Acad
Sci U S A, 105(1), 2008, 252–257.
[8] Rauch T.A., Wang Z., Wu X. et al., DNA methylation
biomarkers for lung cancer. Tumour Biol
J Int Soc Oncodevelopmental Biol Med, 33(2),
2012, 287–296.
[9] Kneip C., Schmidt B., Seegebarth A. et al.,
SHOX2 DNA methylation is a biomarker for
the diagnosis of lung cancer in plasma. J Thorac
Oncol Off Publ Int Assoc Study Lung Cancer,
6(10), 2011, 1632–1638.
[10] Ilse P., Biesterfeld S., Pomjanski N. et al., Analysis
of SHOX2 methylation as an aid to cytology
in lung cancer diagnosis. Cancer Genomics Proteomics,
11(5), 2014, 251–258.
[11] Schmidt B., Liebenberg V., Dietrich D. et al.,
SHOX2 DNA methylation is a biomarker
[12] Ho T.H., Dang K.X., Lintula S. và cộng sự.
(2015). Extendable blocking probe in reverse
transcription for analysis of RNA variants with
superior selectivity. Nucleic Acids Res, 43(1),
2010, e4.
[13] Song P, Wu LR, Yan YH et al., Limitations and
opportunities of technologies for the analysis of
cell-free DNA in cancer diagnostics. Nat Biomed
Eng. 2022 Mar;6(3):232-245. doi: 10.1038/
s41551-021-00837-3. Epub 2022 Jan 31. PMID:
35102279; PMCID: PMC9336539.
[14] Vo T.T.L., Nguyen T.N., Nguyen T.T. et al.,
SHOX2 methylation in Vietnamese patients
with lung cancer. Mol Biol Rep, 49(5), 2022,
3413–3421.